Walmart has broadened its Better Care Services platform to include a bundled weight‑management program for customers using or considering GLP‑1 therapies. The new offering combines virtual care, nutrition coaching and pharmacy access, allowing patients to obtain GLP‑1 medications—such as the newly FDA‑approved oral option Foundayo™ (orforglipron, approved April 1, 2026)—through Walmart’s nationwide pharmacy network.
The service will reach more than 40% of U.S. households, a figure that reflects the fact that over 40% of adults live with obesity. Same‑day delivery can be completed in as little as an hour, and Walmart+ members receive free delivery. A dedicated GLP‑1 digital hub on Walmart.com, integrated with LillyDirect, gives customers a single portal to browse medications, nutrition resources and schedule appointments.
Walmart has partnered with a roster of nutrition‑support providers—Aaptiv, Berry Street, Curai Health, MyCare by Twin Health and Wheel—to deliver the coaching component. The expansion taps a rapidly growing obesity market and positions Walmart as a comprehensive health‑care partner, aligning with the company’s broader strategy to deepen its footprint in the health‑care sector.
Kevin Host, Senior Vice President of Pharmacy at Walmart U.S., said, “Weight management today is often difficult to navigate. By bringing together pharmacist support, virtual care and nutrition resources… we’re making it easier for customers to access care and support in a way that fits their lives.”
The initiative is expected to generate new revenue streams and strengthen customer engagement, though Walmart has not disclosed specific financial projections. It signals a strategic shift toward integrated health services that can capture a share of the expanding GLP‑1 market, which now includes an oral option and is set to broaden further with Medicare Part D beneficiaries gaining access through the upcoming Medicare GLP‑1 Bridge demonstration.
The move comes amid a broader trend of retailers expanding health offerings beyond traditional pharmacy services. Amazon is also investing heavily in digital health, and the availability of oral GLP‑1 therapies like Foundayo expands patient access, potentially accelerating adoption and creating a competitive advantage for Walmart’s integrated care model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.